Clinical Trial: A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Duchenne Muscular Dystrophy (DMD)
Study Type: INTERVENTIONAL
Official Title: An Open-label, Single-center, 4-week Phase I Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GRT6019 in Healthy Male Participants
Brief Summary:
The purpose of this trial is to assess the safety, tolerability, and PK of 3 doses of GRT6019 in healthy male participants.This Phase I trial will be a multiple dose trial in healthy male participants with administration of GRT6019 in 3 cohorts.For each participant, the trial consists of a Screening Period of up to 28 days, a 4 week Treatment Period (including a 2-week clinic stay and 2 weeks in an outpatient setting), and a 5 week Follow-up Period.
Read more